all report title image
  • Published On : Mar 2022
  • Code : CMI4965
  • Industry : Biotechnology
  • Pages : 220
  • Formats :

The IPV are very safe. At the site of injection pain or mild redness may occur. To preventfrom Poliomyelitis, which affects children under age of 5. This infection can turn into irreversible paralysis and can also cause death. There are two types of vaccines used: an inactivated poliovirus given by injection (IPV) and a weakened poliovirus given orally (OPV). After two doses of inactivated polio vaccine, 90% or more of individuals develop protective antibodies to all three serotypes, when inactivated polio vaccine injection is used and about 99% are immune to polio virus.

Immunity induced by IPV and its duration is not known with certainty, although to provide protection for several years the complete study has been done. In 1990s IPV replaced the oral vaccines due to risk of vaccine-derived polio in oral vaccines in various countries.

The IPV vaccines market is estimated to be valued at US$ 160 Mn in 2021 and is expected to register a CAGR of 8.5% and reach US$ 240 Mn by 2028.

Figure 1. Global IPV Vaccines Market (US$ Mn), By Vaccine Brand, 2021

IPV Vaccines  | Coherent Market Insights

Figure 1.1. Global IPV Vaccines Market (US$ Mn), By Vaccine Brand, 2028

IPV Vaccines  | Coherent Market Insights

CMI table icon

IPV Vaccines Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 160 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 8.5% 2028 Value Projection: US$ 240 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Vaccine Brand: Poliovac (Pfs/Sd), Shanipv, Poliorix, Ipol/Imovax, Polymilex
  • By Distribution Channel: Private, Public  
Companies covered:

GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio Farma, and AJ Vaccines

Growth Drivers:
  • Rising government support to increase immunization
  • Increasing initiatives by key players to develop and launch inactivated polio vaccines
  • High demand for inactivated polio vaccines (IPV)
Restraints & Challenges:
  • Side effects associated with immunization and high cost of inactivated polio vaccines
  • Introduction of combination vaccines
Opportunities:
  • GAVI (Global Alliance for Vaccines and Immunizations) support to eradicate polio

Figure 2.  Global IPV Vaccines Market (US$ Mn), By Region, 2021

IPV Vaccines  | Coherent Market Insights

Figure 2.1. Global IPV Vaccines Market (US$ Mn), By Region, 2028

IPV Vaccines  | Coherent Market Insights

For instance, in August 2018, Health Ministry of Brazil launched a polio vaccination campaign in Brazil to immunize more than 11.2 million children aged 5 years. The Health Ministry purchased 28.3 million doses of polio vaccines from Brazilian. Moreover, states in Brazil were supplied 871.3 thousand doses of IPV, and 14 million doses of OPV.

Global IPV Vaccines Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. The shutdown disrupted the supply, distribution, and manufacturing of medical supplies globally. Moreover, due to social distancing, the footfall in clinics and health institutions has fallen by more than 70% during this pandemic, which has led to decrease in the number of surgical procedures, clinical trials, research and development activities and others, which has negatively impacted the market growth.

Vaccine hesitancy has been considered a problem for polio eradication in past for Pakistan and Afghanistan. The COVID-19 vaccines had made a widespread awareness regarding lifesaving effects of the vaccines, and this effected on the public awareness in polio endemic countries (Gabon, Ghana, Guinea, Liberia, Nigeria). Especially in the tropics there is need for booster doses of polio vaccine. In routine immunizations, there is need to implement GPEIs, for the oral polio vaccines, which can help in reducing the polio cases by more than 90%. To protect the lives of children, the COVID-19 vaccination centers remain ideal to increase the awareness of polio vaccines.

Global IPV Vaccines Market - Restraint

Inactivated polio vaccines are given to millions of children and adults for the prevention of polio. Although, in some cases, this immunization shows side effects including: rash, itching.

According to several research studies, immunization with inactivated polio vaccines are less effective. For instance, inactivated polio vaccines (IPV) weaken immunity in the intestine. Moreover, after immunization with IPV, every person gets infected with wild poliovirus, which multiply in the intestines.

Therefore, these side effects can pose major challenges such as decreasing community acceptance for such inactivated polio vaccines, which in turn is expected to hamper growth of Global Inactivated Polio Vaccines Market.

High cost of inactivated polio vaccines in comparison with oral polio vaccines may negatively impact growth of the inactivated polio vaccines market.

For instance, in 2019, according to the World Health Organization, the weighted average price of IPV vaccines per dose is US$ 2.8 while the price per dose of OPV vaccine ranges from US$ 0.12 to 0.17 in PAHO countries.

Key Players

Major players operating in the Global IPV vaccines market include GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio Farma, and AJ Vaccines.

Inactivated polio vaccine (IPV) is also known as Salk vaccine. For the vaccination against polio there are two vaccines available: inactivated polio vaccine and oral polio vaccine. The IPV vaccine is mostly given in arm or leg as a shot.

Individuals who are allergic to eggs or the drugs such as streptomycin should not receive the injectable IPV. The IPV is only given if the vaccine recipient is on steroid therapy for long-term, has cancer, or is on ongoing process of chemotherapy or there is any unimmunized adult in house.

Global IPV vaccines market was valued at US$ 160 Mn in 2021 and is expected to increase to US$ 240 Mn by 2028, registering a CAGR of 8.5% over the forecast period.

Market Dynamics

Various governments have taken initiatives to increase awareness regarding vaccination to prevent occurrence of polio among the population. Public introduced beneficial immunization programs to provide vaccination to poor people, which is expected to create a highly conducive environment for growth of the Global Inactivated Polio Vaccines Market (IPV) in the near future. For instance, in September 2019, the Ghana Health Service (GHS), launched series of polio vaccination/immunization campaign to prevent spreading of the virus in high risk areas. The immunization polio vaccination campaign will use the inactivated polio vaccine (IPV) to immunize all the children born from January 2016 to June 2018 in all districts across Ghana.

Key features of the study:

  • This report provides in-depth analysis of the Global IPV vaccines market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Global IPV vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio Farma, and AJ Vaccines
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The IPV vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global IPV vaccines market

Detailed Segmentation:

  • Global IPV Vaccines Market, by Vaccine Brand:
    • Poliovac (Pfs/Sd)
    • Shanipv
    • Poliorix
    • Ipol/Imovax
    • Polymilex
  • Global IPV Vaccines Market, by Distribution Channel:
    • Private
    • Public
  • Global IPV Vaccines Market, by Region:
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles:
    • GlaxoSmithKline Plc*
      • Company highlights
      • Product Portfolio
      • Key Highlights
      • Financial performance
      • Strategies
    • Sanofi S.A.
    • Serum Institute of India Pvt. Ltd.
    • PT Bio Farma
    • AJ Vaccines

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The IPV vaccines market is estimated to be valued at US$ 160 million in 2021 and is expected to exhibit a CAGR of 8.5% over the forecast period (2021-2028).
The Rising government support to increase immunization, Increasing initiatives by key players to develop and launch inactivated polio vaccines, High demand for inactivated polio vaccines (IPV) are the major factors which are expected to drive the market growth over the forecast period. 
IPOL/IMOVAX is expected to hold major market share over the forecast period.
Latin America holds the largest market share in the market. Increasing initiatives such as polio vaccination campaigns by governments in Brazil, Venezuela, and other countries is expected to contribute to growth of the Latin America inactivated polio vaccines market.
Major factors hampering growth of the Global IPV vaccines market include side effects associated with immunization, high cost of inactivated polio vaccines, and introduction of combination vaccines.
Major players operating in the market include GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio Farma, and AJ Vaccines.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo